Atrial Flutter

Atrial flutter is a supraventricular tachyarrhythmia characterized by a rapid, regular atrial activation rate (typically 240-400 beats per minute in dogs and cats) with a characteristic sawtooth pattern on the electrocardiogram (ECG). It results from a macro-reentrant circuit within the atria, most commonly involving the right atrium, and is often associated with underlying structural heart disease. In veterinary medicine, atrial flutter is less common than atrial fibrillation but shares similar clinical consequences, including reduced cardiac output, exercise intolerance, and risk of thromboembolism. The arrhythmia may be paroxysmal, persistent, or permanent, and its clinical significance depends on the ventricular response rate, duration, and presence of concurrent cardiac disease.

Atrial flutter is typically a secondary arrhythmia, arising from conditions that cause atrial enlargement, fibrosis, or inflammation. Primary etiologies include: chronic valvular heart disease (especially myxomatous mitral valve degeneration in dogs), dilated cardiomyopathy (Doberman Pinschers, Boxers), hypertrophic cardiomyopathy (cats), congenital heart diseases (e.g., atrial septal defect, tricuspid valve dysplasia), and pericardial diseases. Other causes include hyperthyroidism (feline), systemic hypertension, electrolyte imbalances (hypokalemia, hypomagnesemia), hypoxia, acid-base disturbances, and drug toxicities (e.g., digoxin toxicity, sympathomimetics). In rare cases, atrial flutter may occur as an idiopathic or primary electrical disease, particularly in large-breed dogs with no detectable structural heart disease.

Atrial flutter is uncommon in veterinary patients compared to atrial fibrillation. It is most frequently diagnosed in dogs with severe atrial enlargement secondary to chronic valvular disease or dilated cardiomyopathy. Large-breed dogs, such as Doberman Pinschers, Boxers, and Irish Wolfhounds, may be overrepresented due to their predisposition to myocardial disease. In cats, atrial flutter is rare but may occur in association with hypertrophic cardiomyopathy or hyperthyroidism. There is no clear sex predilection, and the condition typically affects middle-aged to older animals, reflecting the age distribution of underlying cardiac diseases. Breed-specific genetic predispositions to atrial remodeling may contribute, but specific genetic markers have not been identified.

The pathophysiological basis of atrial flutter is a macro-reentrant circuit, typically located in the right atrium, that propagates in a circular or figure-of-eight pattern. The reentrant circuit is sustained by a critical balance between conduction velocity and refractory periods, often facilitated by atrial enlargement, fibrosis, and heterogeneous refractoriness. The rapid atrial rate (typically 300-400 bpm in dogs) is conducted to the ventricles with varying degrees of atrioventricular (AV) block, usually 2:1 or 3:1, resulting in a ventricular rate of 150-200 bpm. This rapid ventricular rate reduces diastolic filling time, decreases stroke volume, and increases myocardial oxygen demand, potentially leading to hypotension, pulmonary congestion, and myocardial ischemia. Chronic tachycardia can induce tachycardia-induced cardiomyopathy, further impairing ventricular function. Additionally, loss of atrial mechanical contraction increases the risk of thrombus formation, particularly in the left atrial appendage, predisposing to systemic thromboembolism.

Predisposing factors include any condition that causes atrial enlargement or structural remodeling, such as chronic mitral valve disease, dilated cardiomyopathy, and congenital heart defects. Electrolyte disturbances, particularly hypokalemia and hypomagnesemia, can alter atrial refractoriness and promote reentry. Hypoxia and acid-base imbalances increase atrial irritability. Hyperthyroidism in cats increases beta-adrenergic tone and may precipitate atrial flutter. Drugs that prolong atrial conduction or alter refractoriness, such as digoxin, sympathomimetics, and certain anesthetics, may also predispose. Advanced age and breed-related myocardial disease are additional risk factors.

Clinical signs vary depending on the ventricular rate, duration of arrhythmia, and severity of underlying heart disease. In peracute or acute presentations, animals may show weakness, collapse, or syncope due to hemodynamic compromise. Subacute and chronic cases often present with exercise intolerance, lethargy, dyspnea, coughing (if congestive heart failure develops), and inappetence. Physical examination findings include tachycardia with a regular or irregularly irregular pulse (if variable AV block), weak femoral pulses, pale mucous membranes, prolonged capillary refill time, and auscultation of a rapid heart rate with possible murmurs or gallop sounds. Signs of congestive heart failure, such as pulmonary crackles, jugular venous distension, and ascites, may be present. In cats, clinical signs may be more subtle, including lethargy and respiratory distress.

Differential diagnoses include: (1) Atrial fibrillation: irregularly irregular rhythm, no P waves, fibrillatory waves; (2) Atrial tachycardia: P waves with abnormal morphology, rate typically 240-300 bpm, often with variable AV block; (3) Sinus tachycardia: P waves present, rate <240 bpm, gradual onset/offset; (4) Ventricular tachycardia: wide QRS complexes, AV dissociation, fusion beats; (5) Supraventricular tachycardia with aberrant conduction: may mimic ventricular tachycardia; (6) Atrial premature complexes: early P waves, not sustained; (7) Sick sinus syndrome: bradyarrhythmias with episodic tachyarrhythmias; (8) Hyperthyroidism-induced tachyarrhythmias: elevated T4, weight loss, polyphagia. Definitive differentiation relies on ECG analysis, Holter monitoring, and response to vagal maneuvers or adenosine (in research settings).

The diagnostic approach begins with a thorough history and physical examination, followed by a 6-lead ECG to document the arrhythmia. If atrial flutter is suspected, a vagal maneuver (e.g., carotid sinus massage) may be attempted to slow the ventricular rate and reveal flutter waves. If the ECG is inconclusive, a 24-hour Holter monitor may be used to capture paroxysmal episodes. Thoracic radiographs are essential to assess cardiac size, pulmonary vasculature, and evidence of congestive heart failure. Echocardiography is the gold standard for identifying underlying structural heart disease, measuring atrial dimensions, and assessing ventricular function. Blood work, including serum biochemistry, thyroid hormone levels (in cats), and cardiac biomarkers (NT-proBNP, troponin I), helps identify systemic or metabolic triggers. In refractory cases, intracardiac electrophysiological studies may be performed at specialized centers to map the reentrant circuit.

Complete blood count (CBC) is often unremarkable unless there is an underlying inflammatory or infectious process. Serum biochemistry may reveal electrolyte imbalances (hypokalemia, hypomagnesemia), renal or hepatic abnormalities, and elevated liver enzymes due to passive congestion. In cats, serum T4 should be measured to rule out hyperthyroidism. Cardiac biomarkers: NT-proBNP is often elevated in animals with atrial stretch or heart failure; troponin I may be elevated if myocardial injury is present. Arterial blood gas analysis may show hypoxemia or acid-base disturbances in animals with respiratory compromise. Urinalysis is generally unremarkable but may show proteinuria if hypertension is present. In cases of suspected myocarditis, serology or PCR for infectious agents (e.g., Borrelia, Ehrlichia) may be considered.

Thoracic radiographs typically show cardiomegaly, left atrial enlargement (evidenced by a bulge in the caudal cardiac silhouette), pulmonary venous congestion, and interstitial or alveolar pulmonary infiltrates in cases of congestive heart failure. Echocardiography is the primary imaging modality: it reveals atrial dilation (left atrial-to-aortic root ratio >1.6 in dogs, >1.5 in cats), ventricular hypertrophy or dilation, valvular lesions, and reduced systolic function (ejection fraction <40% in dilated cardiomyopathy). Doppler echocardiography can assess diastolic function and estimate pulmonary artery pressure. Advanced imaging such as cardiac MRI or CT is rarely needed but may be used to evaluate atrial anatomy and fibrosis in research settings.

Cytology and histopathology are not typically performed for atrial flutter itself, but they may be indicated to diagnose underlying myocardial disease. Endomyocardial biopsy (rarely performed in veterinary patients) may show myocyte hypertrophy, interstitial fibrosis, or inflammatory infiltrates in cases of myocarditis. Histopathological findings in dilated cardiomyopathy include myocyte attenuation, nuclear enlargement, and interstitial fibrosis. In chronic valvular disease, the valve leaflets show myxomatous degeneration. These findings are not specific to atrial flutter but help characterize the underlying pathology.

Treatment goals are to control the ventricular rate, restore normal sinus rhythm if possible, manage underlying heart disease, and prevent thromboembolism. Emergency stabilization: If the animal is hemodynamically unstable (hypotension, pulmonary edema, syncope), immediate synchronized direct-current cardioversion (0.5-1 J/kg) is indicated. Medical rate control: Diltiazem (0.5-1.5 mg/kg PO q8h or 0.1-0.3 mg/kg IV bolus followed by CRI at 2-6 mcg/kg/min) is the first-line agent to slow AV conduction. Beta-blockers such as atenolol (0.25-1 mg/kg PO q12h) or esmolol (50-100 mcg/kg IV bolus, then 50-200 mcg/kg/min CRI) may be used, but with caution in animals with heart failure. Digoxin (0.005-0.01 mg/kg PO q12h) may be added for long-term rate control, but its use is limited by narrow therapeutic index. Antiarrhythmic drugs for rhythm control: Amiodarone (10-15 mg/kg PO q12h for 7 days, then 5-10 mg/kg q24h) or sotalol (1-2 mg/kg PO q12h) may be used to convert to sinus rhythm, but they have proarrhythmic risks. In refractory cases, catheter-based radiofrequency ablation of the reentrant circuit is an option at specialized centers. Supportive care includes oxygen therapy for respiratory distress, diuretics (furosemide 1-2 mg/kg IV or PO q8-12h) for congestive heart failure, and ACE inhibitors (enalapril 0.5 mg/kg PO q12h) for remodeling. Antithrombotic therapy: Aspirin (5 mg/kg PO q24h) or clopidogrel (2-3 mg/kg PO q24h) may be considered, though evidence is extrapolated from atrial fibrillation.

The prognosis depends on the underlying cause, ventricular rate control, and response to therapy. Animals with reversible triggers (e.g., hyperthyroidism, electrolyte imbalances) may have a good prognosis if the trigger is corrected. In dogs with chronic valvular disease, the development of atrial flutter indicates advanced disease and a guarded prognosis, with median survival times of 6-12 months despite treatment. Cats with hypertrophic cardiomyopathy and atrial flutter have a poor prognosis, with high risk of congestive heart failure and thromboembolism. Negative prognostic indicators include persistent tachycardia, poor rate control, concurrent heart failure, and severe atrial enlargement. With successful rate control and management of underlying disease, some animals can maintain a good quality of life for months to years.

Follow-up should include recheck examinations at 1, 3, and 6 months after initial diagnosis, then every 6-12 months thereafter. At each visit, a physical examination, ECG, and blood pressure measurement should be performed. Serial echocardiography is recommended every 6-12 months to monitor atrial size and ventricular function. Serum electrolyte and renal function should be monitored regularly, especially if diuretics or digoxin are used. Holter monitoring may be repeated if clinical signs recur or if antiarrhythmic therapy is adjusted. Owners should be educated to monitor resting respiratory rate and heart rate at home, and to seek immediate veterinary care if signs of heart failure or syncope occur.

Pearls: (1) Atrial flutter often has a 2:1 AV block, resulting in a ventricular rate of ~150-200 bpm in dogs; vagal maneuvers may increase AV block and reveal flutter waves. (2) Synchronized cardioversion is highly effective for acute conversion; start with low energy (0.5 J/kg) and increase if needed. (3) Diltiazem is preferred over beta-blockers for rate control in animals with concurrent heart failure. (4) Always evaluate for underlying hyperthyroidism in cats with atrial flutter. Pitfalls: (1) Mistaking atrial flutter for sinus tachycardia can lead to inappropriate treatment; always perform a 6-lead ECG. (2) Using digoxin as monotherapy for rate control is often ineffective and may be toxic. (3) Administering antiarrhythmic drugs without addressing electrolyte imbalances can precipitate ventricular arrhythmias. (4) Failing to recognize that atrial flutter may be paroxysmal; a normal ECG does not rule out the diagnosis.

Based on Plumb's Veterinary Drug Handbook, the following protocols are recommended: Diltiazem: Dogs: 0.5-1.5 mg/kg PO q8h; Cats: 1-2 mg/kg PO q8h; IV: 0.1-0.3 mg/kg over 5 min, then CRI 2-6 mcg/kg/min. Atenolol: Dogs: 0.25-1 mg/kg PO q12h; Cats: 0.25-1 mg/kg PO q12h. Esmolol: Dogs: 50-100 mcg/kg IV bolus, then 50-200 mcg/kg/min CRI; Cats: 50-100 mcg/kg IV bolus, then 50-200 mcg/kg/min CRI. Digoxin: Dogs: 0.005-0.01 mg/kg PO q12h; Cats: 0.007-0.01 mg/kg PO q48h (use with caution). Amiodarone: Dogs: 10-15 mg/kg PO q12h for 7 days, then 5-10 mg/kg q24h; Cats: not recommended. Sotalol: Dogs: 1-2 mg/kg PO q12h; Cats: 1-2 mg/kg PO q12h. Furosemide: Dogs: 1-2 mg/kg IV or PO q8-12h; Cats: 1-2 mg/kg IV or PO q8-12h. Enalapril: Dogs: 0.5 mg/kg PO q12h; Cats: 0.25-0.5 mg/kg PO q12h. Clopidogrel: Dogs: 2-3 mg/kg PO q24h; Cats: 18.75 mg/cat PO q24h. Aspirin: Dogs: 5 mg/kg PO q24h; Cats: 5 mg/cat PO q48h. Dosages should be adjusted for renal or hepatic impairment, and therapeutic drug monitoring is recommended for digoxin (target trough 0.8-1.5 ng/mL). Contraindications: Diltiazem should be avoided in animals with severe hypotension or sick sinus syndrome; beta-blockers are contraindicated in uncontrolled heart failure; amiodarone is hepatotoxic and should be used with caution.

Evidence for the management of atrial flutter in veterinary medicine is largely extrapolated from human medicine and small case series. A retrospective study by Saunders et al. (2009) reported that diltiazem effectively controlled ventricular rate in dogs with atrial flutter and fibrillation. A study by Bright and Zumbrunnen (2008) demonstrated that amiodarone was effective in converting atrial flutter to sinus rhythm in dogs, but with significant side effects. ACVIM consensus guidelines on the management of arrhythmias in dogs and cats (2018) recommend rate control as the primary goal, with diltiazem as first-line therapy. Radiofrequency ablation has been described in a few case reports with successful outcomes, but it is not widely available. Overall, the evidence base is limited, and treatment decisions should be individualized based on the underlying disease and patient status.